BCT score predicts chemotherapy benefit in Asian patients with hormone receptor-positive, HER2-negative, lymph node-negative breast cancer

Racial Differences in 21-Gene Recurrence Scores Among Patients With Hormone Receptor–Positive, Node-Negative Breast Cancer

(2018) Andreana N. Holowatyj et al.   JOURNAL OF CLINICAL ONCOLOGY

A new molecular prognostic score for predicting the risk of distant metastasis in patients with HR+/HER2− early breast cancer

(2017) Gyungyub Gong et al.   Scientific Reports

70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer

(2016) Fatima Cardoso et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015

(2015) A. S. Coates et al.   ANNALS OF ONCOLOGY

Prospective Validation of a 21-Gene Expression Assay in Breast Cancer

(2015) Joseph A. Sparano et al.   NEW ENGLAND JOURNAL OF MEDICINE

21-Gene recurrence scores

(2011) Mary Jo Lund et al.   CANCER

The 70-Gene Prognostic Signature for Korean Breast Cancer Patients

(2011) Kuk Young Na et al.   Journal of Breast Cancer

Triple-negative, basal-like, and quintuple-negative breast cancers: better prediction model for survival

(2010) Yoon-La Choi et al.   BMC CANCER

The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer

(2010) Michael Knauer et al.   BREAST CANCER RESEARCH AND TREATMENT

Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial

(2009) Kathy S Albain et al.   LANCET ONCOLOGY

Development of the 21-Gene Assay and Its Application in Clinical Practice and Clinical Trials

(2008) Joseph A. Sparano et al.   JOURNAL OF CLINICAL ONCOLOGY